ECTOP-1022 (NCT06323148) is a phase 3 study that will evaluate the use of adjuvant osimertinib vs. observation in ctDNA-positive patients with stage II–IIIA NSCLC and EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.